Amgen Inc. is a leading biotechnology company that focuses on the discovery, development, and manufacturing of innovative human therapeutics. Founded in 1980, the company is known for its commitment to advancing science and delivering medicines that treat serious illnesses, primarily in the fields of oncology, nephrology, and inflammation. Amgen's core products include biologic therapies such as Enbrel, Neulasta, and Prolia, which are designed to address various chronic and acute health conditions.
As a large-cap company, Amgen holds a significant position in the biotechnology industry, competing with other major players like Gilead Sciences and Biogen. The company has consistently demonstrated strong financial performance, characterized by steady revenue growth and profitability. Amgen is recognized as a value stock, offering a dividend to its shareholders, which reflects its commitment to returning capital while investing in future growth opportunities.
Recently, Amgen has focused on expanding its pipeline through strategic acquisitions and partnerships, as well as investing in research and development to enhance its product offerings. The company is also exploring innovative technologies, including gene therapy and personalized medicine, to remain competitive in the evolving healthcare landscape. This strategic direction aims to position Amgen as a leader in addressing unmet medical needs and improving patient outcomes.